Cepheid receives EUA for its SARS-CoV-2 test

Create PDF

“Cepheid currently has nearly 5,000 GeneXpert systems in the U.S. capable of point-of-care testing and for use in hospitals,” Warren Kocmond, president of Cepheid, said in a press release. “Our automated systems do not require users to have specialty training to perform testing—they are capable of running 24/7, with many systems already doing so today.”